Trince strengthens leadership
Trince strengthens leadership team to accelerate global growth
We are excited to announce an important evolution in Trince’s leadership structure as we enter a new phase of accelerated growth and global expansion.
Kevin Braeckmans, co‑founder and scientific driving force behind our LumiPore™ technology, has been appointed CEO of Trince. Kevin has played a central role in building our technological foundation and translating it into impactful solutions for customers and partners around the world. In his new role, Kevin will focus on executing Trince’s long‑term strategy, leading the team, driving commercial growth, and strengthening partnerships with customers, investors, and industry stakeholders.
At the same time, Philip Mathuis, co‑founder and CEO since the company’s inception, will transition to the role of Executive Chairman of the Board of Directors. As Executive Chairman, Philip will focus on shaping Trince’s long‑term vision, guiding corporate strategy, leading board governance, and strengthening high‑level relationships with investors and strategic partners.
With Kevin driving operational leadership and Philip guiding long‑term strategic direction, Trince is strongly positioned for its next phase of innovation and global expansion.
We are excited about what lies ahead as we continue advancing our technology and bringing impactful solutions to our partners and customers.
Our CEO Philip Mathuis will present at Cell & Gene Meeting on the Mesa
Attention industry pioneers! The Alliance for Regenerative Medicine’s 2024 Cell and Gene Meeting on the Mesa is just around the corner, and our team is looking to connect with the brightest minds.
Our CEO and co-founder Philip Mathuis will present the current and future insights and applications for photoporation.
If you’re attending, send us a note in the partnering system to set up a meeting and view our company presentation on Wednesday, Oct. 9th at 9.45 am.
Trince announces distributor agreement with Meiwafosis
This strategic partnership will significantly bolster our presence in Japan, a global hub for stem cell research and therapies, particularly iPSCs.
By joining forces with Meiwafosis, we aim to expand our commercial footprint and provide Japanese researchers with access to our innovative cell transfection technologies. This collaboration will make cell engineering more gentle and effective, empowering groundbreaking advancements in the field.
Stay tuned for more updates as we embark on this exciting journey together!
Nature Spinoff Prize
Trince, a spin-off from Ghent University, has won the prestigious Nature Spinoff Prize from the scientific journal Nature. This award, which is awarded globally, recognizes spin-offs that translate original, high-quality scientific research into products and services that address market problems and have a positive impact on society. In the final, Trince eventually beat two American and one British opponent.
The EOS is a well-known magazine in Belgium and The Netherlands for popular science. (Dutch only).
Ziektes behandelen met fotoporatie: ‘Je wilt iets in de
cel brengen, maar die tegelijkertijd zo gezond mogelijk
achterlaten’
UGent spin-off nominated for prestigious Nature Spinoff Prize
Trince, an innovative spin-off from Ghent University, is one of four finalists for the global Spinoff Prize from the scientific journal Nature.
This prestigious award is given to spin-offs that translate original, high-quality scientific research into products and services that address market problems and have a positive impact on society. Trince has been nominated for its groundbreaking research into photoporation, a new and safer method of introducing DNA and other molecules into cells, such as in immunotherapy or gene therapy.
The word is out
Very proud to announce that TrinceBio is longlisted for the Nature Spinoff Prize!We are working hard on our non-viral cell engineering platform and are happy to receive recognition for the potential and way forward of our technology.
European Innovation Council Awards
European Innovation Council Awards €2.5 Million Grant to Trince, NecstGen, and IBSAL for Advancing Cell Therapy Manufacturing
The HealthTech Investor Summit
Philip Mathuis pitched on the HealthTech Investor Summit !
Highly Cited Researcher
Our CSO Professor Kevin Braeckmans is again on this year’s Clarivate list of highly cited researchers. We are proud.